Similar articles

• P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

  Verschraagen M, Koks CH, Schellens JH, Beijnen JH. Verschraagen M, et al. Pharmacol Res. 1999 Oct;40(4):301-6. doi: 10.1006/phrs.1999.0535. Pharmacol Res. 1999. PMID: 10527640 Review.
• Use of digoxin for heart failure and atrial fibrillation in elderly patients.

  Cheng JW, Rybak I. Cheng JW, et al. Am J Geriatr Pharmacother. 2010 Oct;8(5):419-27. doi: 10.1016/j.amjopharm.2010.10.001. Am J Geriatr Pharmacother. 2010. PMID: 21335295 Review.
• P-glycoprotein makes no contribution to the lower transplacental transfer of digoxin under fetal heart failure, but who should be blamed for?

  Li Y, Hua Y, Zhou K. Li Y, et al. Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:256-7. doi: 10.1016/j.ejogrb.2014.04.020. Epub 2014 Apr 26. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24798074 No abstract available.
• Optimal digoxin concentrations for patients with heart failure.

  Carbonin P, Zuccalà G. Carbonin P, et al. JAMA. 2003 May 28;289(20):2643; author reply 2643-4. doi: 10.1001/jama.289.20.2643-a. JAMA. 2003. PMID: 12771104 No abstract available.
• Omeprazole does not modulate pharmacokinetic of digoxin in patients with heart failure.

  Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CB. Souza FC, et al. Int J Cardiol. 2015 Jan 20;179:343-4. doi: 10.1016/j.ijcard.2014.11.062. Epub 2014 Nov 7. Int J Cardiol. 2015. PMID: 25464482 No abstract available.